Evidence Based Neonatal Pharmacotherapy

Dr. Spitzer has created an issue devoted to the evidence-based pharmacologic care of the neonate. The issue opens with an important article on A Quality Improvement Approach to Modifying Medication Use in the NICU. The expert authors he has secured have contributed articles in the areas of therapeutic drug monitoring, off-label use of medications in the NICU, antenatal and post-natal corticosteroids, antibiotics, antifungals, and antivirals, as well as bronchodilators and nitric oxide. Other articles also present evidence-based use of oxygen, dopamine, anesthetics and analgesics, and erythropoetin.

Dr. Spitzer has created an issue devoted to the evidence-based pharmacologic care of the neonate. The issue opens with an important article on A Quality Improvement Approach to Modifying Medication Use in the NICU. The expert authors he has secured have contributed articles in the areas of therapeutic drug monitoring, off-label use of medications in the NICU, antenatal and post-natal corticosteroids, antibiotics, antifungals, and antivirals, as well as bronchodilators and nitric oxide. Other articles also present evidence-based use of oxygen, dopamine, anesthetics and analgesics, and erythropoetin.

The premier comprehensive textbook in the field, Yaffe and Aranda’s Neonatal and Pediatric Pharmacology, Fifth Edition, provides an authoritative overview of all aspects of drug therapy in newborns, children, and adolescents. It offers evidence-based guidelines for safe, effective, and rational drug therapy, including specific recommendations for all major drug classes and diseases. Now in a vibrant two-color format, this fully revised reference is an indispensable resource for pediatricians, neonatologists, pediatric residents, and fellows in different pediatric subspecialties, including neonatal medicine and pediatric critical care.

"Neonatal and Pediatric Pharmacology offers guidelines for safe, effective, and rational drug therapy in newborns, children and adolescents. The book provides relevant and useful data on the molecular, physiologic, biochemical, and pharmacologic mechanisms of drug action and therapy in this population. The authors identify areas of innovative basic and translational research necessary for the continuing evaluation and development of drugs for the fetus, newborns, children and adolescents. Neonatal and Pediatric Pharmacology is is a valuable reference for all health care professionals who treat the fetus, newborns, children, and adolescents, including neonatologists, nurses, pediatricians, general practitioners, students, obstetricians, perinatologists, surgeons and allied health professionals. It will be useful anytime during the day and especially in the middle of the night when knowledge of appropriate indications, safe and effective use, dosage, and therapeutic regimen for a certain drug or molecular entity is immediately needed. The book is also directed to those involved in basic, clinical, and other academic pharmacological research, the pharmaceutical industry, and regulatory agencies dealing with drug and therapeutic developments for this population. Those teaching pharmacology and therapeutics will find this compilation of information extremely useful in preparing teaching materials"--Provided by publisher.

Written by experts at the forefront of current research and clinical practice, this volume provides evidence-based guidelines for safe, effective, and rational drug therapy in newborns, children, and adolescents. Coverage includes specific recommendations for all major drug classes and diseases, a detailed section on drugs and the newborn, and chapters on specific treatment settings such as the pediatric intensive care unit and emergency room. Also included are chapters on adverse effects and interactions and state-of-the-art discussions on pharmacokinetics, pharmacodynamics, pharmacogenetics, drug development, and clinical drug trials in infants and children. Appendices include a neonatal formulary and a pediatric formulary.

Written by experts at the forefront of current research and clinical practice, this volume provides evidence-based guidelines for safe, effective, and rational drug therapy in newborns, children, and adolescents. Includes updated information on drug interactions and regulatory issues.

The Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA) were designed to encourage more pediatric studies of drugs used for children. The FDA asked the IOM to review aspects of pediatric studies and changes in product labeling that resulted from BPCA and PREA and their predecessor policies, as well as assess the incentives for pediatric studies of biologics and the extent to which biologics have been studied in children. The IOM committee concludes that these policies have helped provide clinicians who care for children with better information about the efficacy, safety, and appropriate prescribing of drugs. The IOM suggests that more can be done to increase knowledge about drugs used by children and thereby improve the clinical care, health, and well-being of the nation's children.

"This book provides a complete look at neonatal healthcare delivery. This edition includes discussions of contemporary topics of interest, such as informatics, genetics, global health, and family-centered care, which are vital to providers caring for neonates today. The case studies and the evidence-based practice dialogues at the end of each chapter provide great opportunities for further reflection. The book is useful to a wide audience in nursing, including undergraduate and graduate nursing students, practicing neonatal and pediatric nurses, and advanced practice nurses who care for neonates." Score: 92, 4 Stars.--Doody's Medical Reviews This 'classic' has been thoroughly updated to incorporate the most up-to-date research findings and strategies for providing cost-effective and evidence-based care. New chapters address emerging infections, the late preterm infant, and neonatal care from a global perspective. Included are updated neonatal care protocols and procedures, neuroprotective risk factors, new treatments, and new trends in developmental care. Text integrates the Institute of Medicine's (10M) five competencies, reflects the Affordable Healthcare Act and the Robert Wood Johnson and 10M report "The Future of Nursing." The text continues to provide neonatal care from a physiologic and pathophysiologic approach, with a major emphasis on nursing management at the bedside and advanced practice level. Each neonatal body system is presented, along with E-B interventions to assist in understanding the 'why' behind what is seen in the clinical area. Integrative management is threaded through the text along with extensive research findings to support practice strategies and rationales for sound clinical decision-making. Topics of recent interest include iatrogenic complications, neonatal pain, use of computers or other technology in neonatal care, and neonatal AIDS. Case studies enhance understanding of both common and rare neonatal conditions. New to the Fifth Edition: New chapters: emerging infections, the late preterm infant, and neonatal care from a global perspective Updated neonatal care protocols and procedures, neuroprotective factors, new treatment modalities and new trends in developmental care Tackles the UN Millennium Development Goals (MDGs) Addresses the expansion of the nurse's role in the US and worldwide Provides case studies that lead the reader through the identification, diagnosis, treatment, and evaluation of common and rare neonatal conditions